US judge rejects Novo Nordisk bid to block Lilly obesity drug ads

· Health · United States · Denmark

A US federal judge rejected Novo Nordisk's attempt to block Eli Lilly from running television advertisements that Novo alleges are misleading about weight loss drugs. The court found Novo failed to prove that Lilly's campaign, which featured claims of obesity drug superiority, meaningfully harmed the Danish company's sales. The ruling is another setback for Novo in its competition with Lilly in the booming obesity market, where the two companies' GLP-1 drugs are the leading products. The decision allows Lilly's advertising to continue while the broader dispute proceeds. Advertising claims and comparative marketing have become a central battleground as both firms fight for share in a fast-growing category.

Why it matters：Comparative advertising is becoming a real competitive lever in the obesity drug duopoly, and the ruling suggests courts will set a high bar for blocking rival campaigns, shaping how aggressively both companies market to patients and doctors.

Key points

  • Novo alleged Lilly's ads were deceptive about weight loss drug superiority.
  • The judge found Novo did not show meaningful harm to its sales.
  • Lilly's television campaign can continue.

Sources (original reporting)

More stories from this day